Compositions and methods for delivering nutrients

FIELD: chemistry.

SUBSTANCE: invention relates to compositions and methods of delivering water-soluble and lipid-soluble nutrients. A liquid nutritional composition contains an emulsion which contains docosahexaenoic acid, where the emulsion is dispersed in an aqueous component containing at least one of amino acid components selected from a group consisting of: arginine, arginyl-glutamine and alanyl-glutamine; and a protein surfactant containing at least about 90 wt % α-lactalbumin. The α-lactalbumin is present in an amount between about 0.1% and about 1.0% of the nutritional composition. Disclosed is a method for supplemental feeding of a subject, which includes administering said liquid nutritional composition to the subject. The subject can be a premature infant.

EFFECT: invention enables to prevent or correct nutritional deficiency in subjects in need of low-volume supplemental feeding, such as premature infants.

20 cl, 1 dwg, 3 tbl

 

Area of technology

The invention relates to improved compositions for enteral nutrition containing one or more of arginine, glutamine, docosahexaenoic acid (DHA) and arachidonic acid (ARC), and also ways to provide additional power small volume in the form of soluble in water and soluble in lipids nutrients for a population of subjects suffering from nutritional deficits, such as babies born prematurely. Liquid food composition of the present invention may contain an emulsion of DHA, a highly stable α-lactalbumin, which can be dispersed in an aqueous component containing nutrients, such as arachidonic acid (ARC), arginine, glutamine, arginyl-glutamine dipeptide, alanyl-glutamine dipeptide, other amino acids, vitamins, minerals and extra nutrients or a combination of the preceding. The food composition may be convenient for delivery via a nasogastric tube for gastric feeding, transpyloric the introduction and/or any other means of introduction, which lead to the introduction of food composition in the digestive tract of the subject.

The level of technology

The present invention relates to improved enteral nutritional composition that refers to food�Vym deficits in a population of seriously ill patients as well as physiological and other effects, often resulting from those deficits. In particular, the invention refers to food shortages that may occur in subjects receiving fully or partially parenteral nutrition.

Supplementary feeding of an infant who was born prematurely, is very important, as short-term survival and long-term growth and development are under threat. An important goal in providing supplementary feeding for premature infants include the stimulation of growth and accretion of nutrients that are equivalent to those achieved during embryonic development, optimizing the results of neurological development and to build solid foundations for long-term health. However, these goals are not easily achievable, because seriously ill, prematurely born infants with low birth weight are often unable to tolerate traditional enteral nutrition because of comorbidities or immaturity of the gastrointestinal tract and other organ systems. Thus, total parenteral nutrition (TPN) is shown either as the only or preferred method of providing nutritional support. And although the SPT may be vital, it is not a perfect tool for additional power. In the SPT are missing many critical nutrients, � their deficiencies can have long-term physiological consequences and implications, the repercussions for babies.

Indeed, the SPT provides valuable nutrients such as glutamine. Glutamine is traditionally classified as "non-essential" amino acid because it can be synthesized endogenously in almost all tissues. Glutamine is important for development because it is the primary fuel for rapidly dividing cells such as enterocytes of the intestine and lymphocytes.

In healthy subjects consuming a normal diet, there is no need for extra glutamine. However, in critically ill patients with severe catabolism, such as the very sick and/or preterm infants, intracellular glutamine reserves can become depleted, and the biosynthetic pathway are often unable to meet the increased needs of the metabolizing tissues glutamine; glutamine thus becomes a "conditionally essential" amino acid.

At premature birth prematurely born infant is faced with the sudden cessation of placental glutamine delivery. In addition, these babies are often critically ill and faced a number of physiological stress, which can quickly exhaust their available reserves of glutamine. This problem is enhanced by the lack of glutamine in parenteral� nutrition and amino acid solutions SPT. In the sources of parenteral nutrition is often lacking glutamine due to its instability in solution.

Similarly, there are several factors placing preterm infants receiving assistance in the form of PPP in the zone of danger of arginine deficiency. Arginine is an essential amino acid for maximal growth of young mammals. L-Arginine is synthesized in humans from glutamine, glutamate and Proline through the axis of the intestine-kidneys. More specifically: citrulline is synthesized from glutamine, glutamate and Proline in the mitochondria of enterocytes of the intestine, is released from the small intestine and is absorbed primarily by the kidneys to obtain arginine. In human infants the majority of citrulline synthesized in the enterocytes, locally transformed into arginine. L-Arginine is a substrate for the synthesis of nitric oxide (NO), a potent vasodilator in the systemic circulation, gastrointestinal and pulmonary circulation. Endothelial nitric oxide (NO) is an important regulator of the vascular supply and NO exhibits anti-inflammatory properties and activity of vasodilators, which are involved in maintaining the integrity of the mucosal barrier function of the intestine, regulation of blood flow of the intestinal mucosa under conditions of inflammation or injury and norms�form of further transition from fetal to neonatal circulation.

Arginine is also required for detoxification of ammonia. Consequently, a life-threatening hyperammonemia can occur in premature babies born as a result of arginine deficiency. Preterm infants have underdeveloped ways of synthesis of arginine and reduced intestinal mass for citrulline, therefore, has a reduced ability to endogenous production of arginine and requiring additional arginine in their diets. Therefore, it is important to note that additional arginine can prevent hyperammonemia in preterm infants receiving PPP.

In addition, stress often leads to deprivation of both arginine and glutamine supplementation in preterm infants undergoing intensive care. (Neu J. Glutamine supplements in premature infants: why and how. J Pediatr Gastroe nterol Nutr. 2003; 37(5):533-535.) Still, as discussed previously, commercial SPT solutions do not contain glutamine, and thus they do not include a sufficient amount of arginine.

However, data indicate that arginine is an essential amino acid for preterm infants receiving PPP.

For example, preterm infants with necrotizing enterocolitis and persistent pulmonary hypertension had reduced concentrations of arginine in plasma, and bitstop�spine of arginine may be an important factor limiting the production of NO in this population. It has been shown that the levels of L-arginine in plasma were low in preterm infants and are associated with the severity of respiratory distress syndrome. It was also found that the levels of L-arginine in plasma were low in preterm infants at the time of diagnosis of necrotizing enterocolitis. Accordingly, the addition of arginine in infants of low birth weight shows a decrease in necrotizing enterocolitis, probably due to improvement of microcirculatory blood flow in parts of the intestine due to increased local production of nitric oxide via L-arginine-nitric oxide Santanyi way. (Amin HJ, Zamora SA, McMillan DD, Pick the GH, Butzner JD, Parsons HG, Scott RB. Arginine supplementation prevents necrotizing entercolitis in the premature infant. J Pediatr. 2002; 140(4): 425-431.) It was shown that both glutamine and arginine supplements were safe for babies low birth weight in multicenter trials of intravenous and enteral glutamine supplements. (Poindexter BB, Ehrenkranz RA, Stoll BJ, Wright LL, Poole WK, Oh W, Bauer CR, Papile LA, Tyson JE, Carlo WA, Laptook AR, Narendran V, Stevenson DK, Fanaroff AA, Korones SB, Shankaran S, Finer NN, Lemons JA. Parenteral glutamine supplementation does not reduce the risk of mortality or late-onset sepsis in extremely low birth weight infants. Pediatrics. 2004; 113(5); 1209-1215 and Vaughn P, Thomas P, dark R, Neu J. Enteral glutamine supplementation and morbidity in low birth weight infants. J Pediatr. 2003; 142(6): 662-668.)

It is known that proteins become�tsya into amino acids in the digestive system, and the resulting amino acids are used by humans for growth and development. Also known proteins and peptides that are introduced for therapeutic or prophylactic purposes. Oligopeptides are better absorbed in the intestine than individual amino acids. Accordingly, arginyl-glutamine or alanyl-glutamine can be used as a dipeptide source of arginine and glutamine to great effect in comparison with individual amino acids arginine and glutamine to improve stability of the composition or due to increased solubility and absorption of dimers compared to monomers.

SPT and other parenteral nutritional supplements also provide a small amount of a specially introduced, DHA and ARC. DHA is the omega-3 fatty acid and is the most represented long-chain polyunsaturated fatty acid (DSPNIC) in the brain and retina and is considered necessary for the proper development of brain and eyesight of babies. Although there is a metabolic pathway for the biosynthesis from dietary linolenic acid, this bioenergetic pathway is disadvantageous, and mammals get most of their DHA from DHA, provided through dietary sources. For infants, therefore, the source of DHA is typically breast milk, but DHA usually does�t in parenteral compositions providing preterm infants. Parenteral compositions generally do not provide a sufficient amount of arachidonic acid (ARC). The ARC is the omega-6-DSPNIC, which plays a major role as a structural lipid associated with phospholipids in blood, liver, muscle and other systems of major organs. The ARC is synthesized by elongation and decrease the amount of linoleic acid. Nevertheless, the majority of the ARC must be provided through food. The ARC is particularly important during periods of rapid growth of the body and is, therefore, an important component of food for infants.

Numerous studies have shown that milk for preterm infants without additives does not provide adequate amounts of several nutrients to meet the needs of preterm infants (Davis, D. P., "Adequacy of expressed breast milk for early growth of preterm infants", Archives of Disease in Childhood, 52, p.296-301, 1997). While exact requirements vary among infants due to differences in activity, energy expenditure, efficiency of absorption of food, disease and the ability to use energy for the synthesis of tissue, the currently available parenteral dietary sources are inappropriate.

In addition, the volume of feeding is often poorly tolerated in preterm infants, pitatelnie substances must be ensured to a reasonable extent, often after enteral administration. The appropriate method of enteral feeding for premature infant based on gestational age, birth weight, clinical conditions, and in the opinion of the governing medical staff. The decision about the specific feeding are determined based on the ability of the infant to coordinate sucking, swallowing and breathing. Often, premature infants or infants who are less Mature, weak or ill patients require feeding through a tube, to avoid the risk of aspiration and to save energy.

Nasogastric feeding is commonly used in neonatal intensive care units and can be performed either by using a bolus or by continuous infusion enriched milk or other food additives. Continuous power may be more tolerant for infants with very low birth weight and infants who have previously been intolerant to a food bolus; however, as previously discussed, reduced or deficient food delivery is a concern with the methods of continuous power, known to specialists in this field of technology.

There is therefore a need for stable food compositions and methods that are well tolerated in preterm infants, and that mo�but it is easy to introduce the subjects, suffering from nutritional deficits in forms and ways that will readily be accepted by the subject and caregiver.

Populations, such as premature babies often suffer from nutritional deficiencies because they offer diets that are missing critical nutrients, as described above. Thus, in the art there is a need to provide food compositions containing valuable nutrients that support the development of infants, such as DHA, ARC, arginine and glutamine. Therefore, food composition and methods according to the present invention provide additional enteral nutrition subjects suffering from food deficits to promote optimal health and development through the delivery of important nutrients that are either absent or provided in different quantities in known parenteral nutritional compositions.

Summary of the invention

Briefly, therefore, the present invention is directed to stable food composition to solve the problem of nutrient deficiency in subjects such as premature babies that require additional power small volume, and to methods in order to promote the healthy development of the subject. The present invention provides a composition�and for the introduction of fatty acids, such as DHA and/or ARC, amino acids such as arginine and glutamine and other nutrients to a subject to prevent the development of nutritional deficiencies or correct existing nutritional deficiencies.

In one embodiment of the present invention comprises a food composition containing the emulsion of docosahexaenoic acid (DHA), dispergirovannoyj in an aqueous component containing at least one amino acid component selected from the group consisting of arginine, arginyl-glutamine and alanyl-glutamine and a surfactant containing a highly purified α-lactalbumin.

In another embodiment of the present invention relates to a method for providing additional power to a subject, comprising administering to a subject a dietary composition containing the emulsion of docosahexaenoic acid, dispersed in an aqueous component containing at least one amino acid component selected from the group consisting of arginine, arginyl-glutamine and alanyl-glutamine and a surfactant containing a highly purified α-lactalbumin.

Another variant of implementation contains the method for providing supplementary feeding for premature infants, where the method comprises the enteral administration in preterm infants�Enzo food composition containing emulsion of docosahexaenoic acid, dispergirovannoyj in an aqueous component containing at least one amino acid component selected from the group consisting of: arginine, arginyl-glutamine and alanyl-glutamine, along with an emulsifier containing at least about 95 mass % of α-lactalbumin.

It should be understood that as the preceding General description and the following detailed description present embodiments of the present invention and are intended to provide an overview or framework for understanding the nature and character of the present invention in accordance with the invention. The description serves to explain the principles of the claimed subject matter. Other and further features and advantages of the present invention will be obvious to those skilled in the art after reading the subsequent disclosure.

Brief description of the drawings

Fig.1 is a bar graph showing the synergistic effect of the introduction of Arg-GIn of the dipeptide and DHA to promote healthy eye development by reducing the preretinal neovascularization in a mouse model. Fig.1 provides a graphical generalization of the analysis of the levels of preretinal neovascularization in a mouse model after treatment by feeding via gavage. Chi�La in parentheses in the legend refer to the feeding doses via gavage in g/kg of body weight per day. * indicates P-value > 0,05.

Detailed description of the invention

The present invention provides food compositions and methods for providing additional power in the form of soluble in water and soluble in lipids nutrients any population of subjects suffering from nutritional deficits, such as preterm infants. Full and sufficient disclosure of the present invention(s), including the best way addressed to the specialist in the art, is set forth below in the description.

The present invention additionally provides an improved enteral nutritional composition for the correction of nutritional deficits and method for providing additional enteral nutrition to a subject in a form soluble in water and soluble in lipids nutrients. The present invention provides compositions for the introduction of critical nutrients such as DHA and ARC, amino acids such as arginine and glutamine and other nutrients to prevent the development of nutritional deficits to correct existing nutritional deficiencies and/or to promote the healthy development of the subject.

In the future, "emulsion" means a mixture of two or more immiscible liquids containing dispersed phase and dispersion medium. In one emulsion liquid, called�referred to as the disperse phase, is dispersed in another liquid, called the dispersion medium, the bulk aqueous phase or component. "Surfactant" or "emulsifier" means a surfactant, which can increase the stability of the emulsion. A surfactant is placed on the surface between the dispersed phase and the aqueous phase of the emulsion. Surfactants can increase the stability of the emulsion so that once formed, the emulsion could be shared during the years of storage. "Preterm infant" means an entity born at 37 weeks gestational age. The expression "premature infant" is used interchangeably with the phrase "prematurely born baby".

"Infant low birth weight" means a baby born weighing less than 2,500 grams (approximately 5 pounds, 8 ounces).

"Infant, very low birth weight" means a baby born weighing less than 1,500 grams (about 3 lbs, 4 oz). "Infant" means a subject aged in the range of not more than about one year from birth, and includes infants from 0 to about 12 months adjusted age (the age of the child based on the period of fetal development). The term child includes infants with low birth weight, infants of very low birth weight and preterm young�NAV.

All percentages, fractions and relationships, as used in the present invention are given as weight of the total composition, unless otherwise specified. Food composition of the present invention may also be essentially free of any optional or selected components described in the present invention, provided that the remaining nutritional composition still contains all the necessary components or features described in this invention. In this context, and unless otherwise specified, the term "substantially free" means that the selected composition contains less than a functional amount of the optional component, usually less than 0.1 mass%, and also including zero percent by weight of such optional or selected components.

All references to the characteristics or limitations of the singular of the present invention should include an appropriate feature or limitation of the plural, and Vice versa, unless otherwise specified or clearly implied return the context in which reference is made.

All combinations of method or process steps, as used in the present invention can be performed in any order, unless otherwise specified or clearly implied return the context in which made the combination, to�which is referenced.

Methods and compositions in accordance with the present invention, including components thereof, can include, consist of or consist essentially of the essential elements and limitations of the present invention described in the present description, as well as any additional or optional components, components, or limitations described in the present invention, or otherwise useful in nutritional compositions.

As used in the present invention, the term "about" should be considered in relation to both numbers defined in any range. Any reference to a range should be considered as supporting any subset within that range.

Food composition of the present invention can provide additional food and personalized nutrition for preterm infants, for infants or other patients with unmet nutritional needs. Thus, in some embodiments, the food composition is intended to satisfy particular nutritional requirements of individual subjects such as babies or preterm babies, in a stable liquid formulations in a single dose, standardized caloric content and/or as a concentrate to meet the specific dietary needs of the subject.

In addition, the present from�Britanie provides a food composition for combating nutritional deficiency in the provision of those nutrients, who rely on parenteral or total parenteral nutrition, thus contributing to the healthy development of the subject. Indeed, the nutritional composition provides nutrients such as DHA, which will contribute, for example, vision and nervous system in the infant.

The present invention also provides a method for enteral delivery of nutrients to the subject, which required that nutrients were injected in very small volumes. As used in the present invention, the enteral administration includes feeding via nasogastric tube, gastric feeding, transpyloric the introduction of, or any other method known to those skilled in the art, for the introduction of food composition directly into the digestive tract.

Thus, the present invention addresses the needs of any population, which may require additional enteral nutrition small volume, including, but not limited to, perioperative subjects, one subject with syndrome short digestive tract, pediatric subjects of intensive care and/or any population of any age who are incapable of fully oral nutrition, or who are receiving minimal enteral additionally�e food or SPT. Additionally, in some embodiments, the present invention can provide extra power pet, or lower primates.

Specifically, food composition according to the present invention can ensure babies are healthy nutrients that otherwise are missing due to many factors such as premature birth or trauma. Such nutrients include, but are not limited to these, docosahexaenoic acid (DHA), arachidonic acid (ARC), arginine, glutamine, and any water-soluble or soluble in lipids nutrients can be provided in the food composition of the present invention.

The present invention is directed in at least one embodiment of the to a food composition that delivers a small amount of a specific set of nutrients to a subject. The resulting edible composition may be commercially viable and is practical for use in critical cases, intensive therapy including, but not limited to, in the neonatal intensive care unit (NICU). In some embodiments, the food composition of the present invention contains a system for the enteral delivery of nutrients, by means of which a small but precise amounts of food�o compositions are introduced into the digestive tract of the subject. In some embodiments, the food composition is supplied in a volume dose of about 1 ml. In another embodiment of the nutritional composition may be supplied in amounts up to about 1.5 ml or 2 ml.

The composition may contain a combination of fats to deliver the desired mixture of fatty acids, or may contain a single fatty acid, such as long-chain polyunsaturated fatty acid (DSPNIC) or a combination DSPNIC. DSPNIC usually have a carbon chain length of at least 18. Suitable DSPNIC include, but are not limited to these, α-linoleic acid, linoleic acid, linolenic acid, eicosapentaenoic acid (EPA), arachidonic acid (ARC) and docosahexaenoic acid (DHA). In a variant implementation, the composition comprises DHA. In some embodiments, the lipid component of the food composition contains mainly DHA. In one embodiment, the implementation of both the DHA and the ARC included in the food composition.

In addition, the food composition can be administered one to two times daily or more often by medical professional. The introduction can be initiated immediately after birth and may continue until the subject exists nutritional needs.

The composition may contain a combination of fats to deliver the desired mixture of fatty acids and�and may contain a single fatty acid, such as long-chain polyunsaturated fatty acid (DSPNIC) or a combination DSPNIC. DSPNIC usually have a carbon chain length of at least 18. Suitable DSPNIC include, but are not limited to these, α-linoleic acid, linoleic acid, linolenic acid, eicosapentaenoic acid (EPA), arachidonic acid (ARC) and docosahexaenoic acid (DHA). In a variant implementation, the composition comprises DHA. In some embodiments, the lipid component of the food composition will win mainly DHA. In one embodiment, the implementation of both the DHA and the ARC included in the food composition.

The food composition may contain ω-3 and/or ω-6 DSPNIC. In some embodiments, the food composition may contain between about 5 and about 20 mass % of lipids. Additionally, in one embodiment, the implementation, the food composition comprises a source of DHA-containing DHASCO® and/or a mixture of mushroom oil. The food composition may contain between about 1 and about 5 mass % of DHA in some embodiments. In some embodiments, DHASCO® contains about 40% DHA and a mixture of mushroom oil contains about 15% DHA. The source of DHA may be any source known to those skilled in the art.

In a variant implementation of the nutritional composition comprises a source of the ARC containing ARASCO® and/or �rity mushroom oil. In some embodiments, the implementation component of the ARC of dietary Supplement that contains approximately 30% of a mixture of fungal oil. The food composition may contain between about 1% and about 5 mass % of the ARC in some embodiments. The ARC source can be any source of ARC, known to specialists in this field of technology.

Compositions known to those skilled in the art, may be prone to physical instability due to syneresis and to the formation of redispersion deposition. The instability occurs due to high levels of protein, fat and mineral substances, which must contain known food composition to provide adequate nutrition in a reasonable amount. It is noteworthy that the acidification traditional enteral compositions may also lead to precipitation of the protein and separation of the phases. Precipitiously nutrients, as a rule, may not be transferred back into the solution by shaking, and they do not provide nutritional benefits that are required to stimulate the health of the subject.

However, the food composition of the present invention provides an improved enteral composition which provides an acceptable one portion a small amount of premature infants contains valuable proteins, amino acids and fatty acids, and has a shelf life of at �'ere about one year, due to excellent physical stability. Additionally, the present invention provides a new stabilization system, which basically prevents nutrients landed or was separated from enteral compositions and method of preparation of food compositions, with the same content.

Food composition of the present invention may contain a stable emulsion, optionally containing a stabilizing agent, also called an emulsifier.

The emulsifier may contain microencapsulate, surfactants, emulsion stabilizers, or a combination of the above. In some embodiments, the lipids in the food compositions are in the form of stable emulsions. Emulsions can be stabilized by several mechanisms, which can affect the viscosity, density, particle size and surface tension.

In some embodiments, the implementation stage emulsification may be mechanical stirring, ultrasonic vibrations, heat or a combination of the above. Emulsification may be achieved using any method for emulsification known to specialists in this field of technology. In one embodiment of the Emulsification may include homogenization. In some embodiments, can be applied with multiple�adiya's homogenization.

In some embodiments, the stable emulsion proteins can act as surfactants. Protein surfactants have the ability to reside at the interface water-lipid to reduce the coalescence of the drops. Indeed, protein surfactants can lower the surface tension between two fluids, which leads to Miscibility of the two fluids. The food composition may contain a suitable emulsifier which is soluble in water.

In one embodiment of the composition comprises an emulsion DSPNIC, which stabilized the protein substrate containing α-lactalbumin. Emulsified DSPNIC may contain DHA. α-Lactalbumin acts as a stabilizer, specifically as a surfactant. Additional surfactants, emulsion stabilizers and microencapsulate can be used but are not required to obtain a stable emulsifiable food composition of the present invention.

The structure of α-lactalbumin gives the ability to migrate and to turn on the interface water-lipid, thus creating a thermodynamically stable emulsion. The structure also gives the ability to cooperative binding between them on the surface�section and the water-lipid, which leads to the creation of synergistic surface adsorption effect, allowing you to form a strong, stable emulsion.

Some embodiments of the food composition, such as those that are optimized for preterm infants or critically ill infants may be similar in some characteristics of human breast milk. Indeed, the food composition may include α-lactalbumin, which is the dominant whey protein in human breast milk. The addition of α-lactalbumin to the composition in preterm infants may provide some physiological and nutritional benefits. Similarly, the addition of DHA, the ARC, and arginine and glutamine provides physiological benefits for the baby.

The present invention provides a method for use of α-lactalbumin as a surfactant to stabilize the emulsion, thus reducing the coalescence of the droplets and the subsequent separation of the emulsion food composition. In some embodiments, the food composition comprises between about 0.1% and about 1.0 mass % of α-lactalbumin.

α-Lactalbumin food composition can be highly purified α-lactalbumin. Highly purified α-lactalbumin contains at least about 90 mass % of α-l�chalbury, preferably containing at least about 95 mass % of α-lactalbumin and even more preferably containing at least about 98 mass % of α-lactalbumin. The use of highly purified α-lactalbumin to create a stable emulsion system is unique and profitable, especially since it applies for premature and critically ill infants.

The incorporation of α-lactalbumin in the present food composition can include a water dispersion of α-lactalbumin at a concentration in the range from about 5 to about 30 mg/l in the bulk phase, i.e. in an aqueous component such as water. In addition, the supply of protein can be the concentration of more than about 95 mass % and the concentration of α-lactalbumin more than about 90 mass %. In some embodiments, the food composition comprises between about 0.1% and about 1.0 mass % of α-lactalbumin.

The purity of α-lactalbumin is critical because one of the purposes of the invention is to provide a composition for the delivery of nutrients in a small volume. Thus, it is essential that the component selection for food composition was aimed at such nutrients that most physiologically acceptable. Should be used the most purest fraction of α-lactalbumin�on, available for the purposes of creating the emulsion to minimize the possibility that the increased amount of α-lactalbumin required to stabilize the emulsion, could ultimately adversely affect effective dose of a physiologically acceptable nutrients that can be included in a portion or dose of a small amount of the food composition.

In addition, the choice of highly purified α-lactalbumin increases the hypoallergenic food composition. If the purity of the protein substrate is reduced, the likelihood of allergens, such as β-lactoglobulin increases. Subject receiving inside as described in the present invention the food composition may be a premature baby or a seriously ill patient who have very immature digestive tract. Therefore, exposure to any allergen or impurities can strain the immune response of the subject, and any such reaction is undesirable. Therefore, must use the cleanest protein available to avoid unwanted immune response in a subject. Protein substrate used in the food compositions may contain pretreated or hydrolyzed protein. Protein substrate can be gidrolizirovanny by the method of enzymatic hydrolysis, chemical destruction, f�Zico-mechanical destruction, non-mechanical destruction or combinations of the above.

the pH of the above-mentioned dispersion may be adjusted to levels close to the isoelectric point of from about 4.2 to about 4.5 by the use of acidifying substances. Food acids such as citric acid, can be used as acidifying substances for the regulation of the pH of the food composition. Acidifying substances that can be used in the present nutritional compositions include, but are not limited to these, citric acid and phosphoric acid.

The lipid phase of the dispersion, such as DHA, may be added to the dispersion at a concentration in the range from about 75 to about 300 mg per 100 ml, to deliver the subject of the target about 34 mg of the lipid component in day. In some embodiments, the food composition comprises between about 1 and about 5 mass % DHA.

Water-the element that contains the bulk phase of the emulsion may be any suitable substance, known to those skilled in the art. In one embodiment, the implementation of the bulk phase of the emulsion contains water. To achieve a stable emulsion, the emulsification process may be performed using a single-stage homogenizer at a flow rate of up to about 250 ml/min and between about 5,000 to about 15,000 pounds per square inch at temperatures in the range from about C to about 40°C, ±2°C.

High pressure is applied to the dispersion to ensure homogenization. Ultrasonic treatment can be used for dispersing α-lactalbumin and its introduction into the surface layer emulsification droplets during their formation.

The emulsion obtained in accordance with the process described above, contains droplets of oil/lipid in the range of from about 0,070 μm to about 1 μm in diameter. Other nutrients and components, such as amino acids, vitamins and useful minerals can be included in the aqueous phase or element of the emulsion. It may be advantageous to add such other ingredients by mixing directly with the emulsion after homogenization. Indeed, stable α-lactalbumin emulsion allows to incorporate other nutrients in the water element without desorption, destruction or coalescence of the lipid droplets. In addition, in some embodiments, the food composition comprising the emulsion, is on its nutritional properties full that contains suitable types and amounts of lipids, carbohydrates, proteins, vitamins and minerals to be the only food source entity.

The composition may further contain essential amino acids such as arginine and/or glutamine. Amino acids may be�ü represented in any form, which can be taken orally and absorbed. Accordingly, arginyl-glutamine or alanyl-glutamine can be used as a dipeptide source of arginine and glutamine instead of individual amino acids arginine and glutamine to improve the stability of the composition or due to increased solubility and ability to be absorbed dimers compared to monomers.

In some embodiments, the food composition comprises glutamine-glutamine is a dipeptide, glycyl-glutamine dipeptide, N-acetyl-glutamine or other stable in water analogs of glutamine.

Arginine is an essential amino acid for infants. Decreased levels of plasma arginine may reflect respiratory distress syndrome or may be associated with necrotizing enterocolitis; however, signs of necrotizing enterocolitis may be facilitated by the addition of arginine. Thus, food composition according to the present invention can contain the arginine to about 250 mg/ml. In some embodiments, the composition comprises less than about 225 mg/ml arginine, and in other embodiments, the composition comprises less than about 216 mg/ml arginine.

In addition, in some embodiments, the food composition may contain between about 15 and about 20 mass % of arginine. In one Varian�e implement dietary composition offers of 500 mg/kg/day of arginine to the subject.

Similarly, glutamine has important effects on the functioning of the immune system and is especially beneficial for intestinal cells. In addition, infants with low birth weight receiving glutamine may have reduced the need for artificial ventilation of the lungs. Thus, the food composition may contain stable in water in the form of glutamine, which can be delivered in the form of alanyl-glutamine dipeptide or arginyl-glutamine dipeptide. Alanyl-glutamine dipeptide can be preferred before arginyl-glutamine is a dipeptide due to its commercial availability and relatively efficient method of synthesis.

In one embodiment, the implementation is useful to provide arginine and glutamine in the form of an arginyl-glutamine dipeptide, which has excellent solubility in water and bioavailability in humans and animals. In one form, arginyl-glutamine dipeptide is N-terminal amino acid is arginine and the C-terminal amino acid is glutamine. The use of Arg-Gln as a dipeptide, and not as individual amino acids, is preferred due to improved stability, increased solubility and enhanced absorption of the dimer compared to the monomer.

In one embodiment, arginine, glutamine and/or arginyl-glutamine or alanyl-CH�taming the dipeptides can be used to prevent proliferation of abnormal blood vessels in the retina of the infant or preterm infant. The expression "dipeptides" refers at least to arginyl-glutamine is the dipeptide and alanyl-glutamine is the dipeptide. Thus, in some embodiments, the food composition supports the healthy development of vision. In an embodiment, the combination of arginine and glutamine or arginyl-glutamine dipeptide(s) are introduced to the subject in an amount which is effective to prevent abnormal vascular proliferation. This amount can be from about 0.001 to about 10,000 mg/kg-day (where units mg/kg-day treat mg combination of arginine and glutamine in about equimolecular quantities or mg Arg-Gln dipeptide per kg of body weight of the subject per day). The food composition may contain less than about 400 mg/ml arginyl-glutamine, including up to 375 mg/ml arginyl-glutamine in some embodiments, and up to about 387 mg/ml in other embodiments. In certain embodiments, the food composition may contain between about 100 and about 400 mg/ml arginyl-glutamine.

The food composition may contain less than about 300 mg/ml alanyl-glutamine, including up to about 280 mg/ml alanyl-glutamine in some embodiments, and up to 269 mg/ml in other embodiments, implementation.

In some embodiments, the food composition comprises between about 8 and about 12 mass % Alan�l-glutamine. In one embodiment, the implementation of food composition provides the subject of 300 mg/kg/day alanyl-glutamine. The addition of nutrients that have a high nutritional value, such as, for example, arginine and alanyl-glutamine dipeptide to food composition preferably after homogenization to minimize any loss of such valuable nutritional components.

In addition, in some embodiments, the food composition contains both DHA and Arg-Gln. Embodiments of the food composition comprising DHA and Arg-Gln, can promote the healthy development of vision and the nervous system in the infant.

For example, as shown in Fig.1, Arg-Gln dipeptide entered along with DHA, can show a synergistic effect, which greatly reduces the preretinal neovascularization in infants. Fig.1 shows the effects of compounds introduced in a mouse model of oxygen-induced retinopathy (KIR), showing a summary of the results of the analysis of the levels of preretinal neovascularization in a mouse model of CYRUS.

Feeding via gavage with Arg-Gln of the dipeptide showed a dose-dependent reduction in preretinal of neovasculature, similar from intraperitoneal injection of Arg-Gln dipeptide with 5 g/kg body weight/day, reducing the preretinal neovascularization to 39±6% (P>0,05) with respect to the medium as a control. Feeding che�ithout gavage with DHA (2.5 g/kg body weight/day also reduced the preretinal neovascularization to 49±4% (P> 0,05). Feeding via gavage with Arg-Gln of the dipeptide (5 g/kg body weight/day) and DHA (2.5 g/kg body weight/day) showed a synergistic effect with the reduction of preretinal neovascularization to 31±4% (P>0,05).

Along with amino acids or dipeptides composition according to the present invention may contain an additional nitrogen source (i.e., other amino acids and/or protein(s)).

Food composition of the present invention may further comprise flavoring, flavor enhancers, sweeteners, pigments, vitamins, minerals, therapeutic components, functional food ingredients, food ingredients, processorsa components or combinations of the above.

The food composition may also need to include any number of proteins, peptides, amino acids, fatty acids, probiotics and/or their metabolic by-products, prebiotics, carbohydrates and any other nutrients or other compounds that can provide many nutritional and physiological advantages for the subject. The carbohydrates used in food composition can be any of digestible carbohydrates, such as glucose, fructose, sucrose, maltose, maltodextrin, dried corn syrup, or a mixture of the above depending on the application. Hydrolysis�projected carbohydrates can be desirable because of their easy digestibility.

In some embodiments, the food composition of the present invention further comprises at least one prebiotic. In this embodiment, the implementation can be added to any prebiotic known to the person skilled in the art. In a specific embodiment, the implementation of prebiotic can be selected from the group consisting of fruit-oligosaccharide, gluco-oligosaccharide, galacto-oligosaccharide, isomalto-oligosaccharide, Xylo-oligosaccharide and lactulose.

The present invention additionally provides a method of manufacturing a food composition containing the emulsion. The method includes turning in an emulsion of a lipid component with the protein surface-active substance to form a stable product, as previously described. Accordingly, the present invention provides methods for minimizing the degradation of nutrients, including DSPNIC, in a stable composition, such as a food composition.

Food composition of the present invention may be in an industrial scale Packed in such a way that it can be interfaced directly with the enteral feeding devices including, but not limited to, nasogastric tubing, percutaneous endoscopic gastrotomy, percutaneous endoscopic anastasiu, transparency hose, etc. This design�Ktsia convenient, to ensure complete delivery of the contents of the package, to minimize the risk of contamination and increase compatibility. Additionally, in certain embodiments, the food composition may be packaged in packaging to deliver a single dose of the total volume of about 1 ml, total volume of about 1.5 ml, or the total volume of about 2 ml.

The food composition may be administered directly into the intestinal tract of the subject. In some embodiments, the food composition is delivered directly into the digestive tract. In some embodiments, the composition may be formulated to be consumed or administered enteral way under the supervision of a physician and may be intended for the specific dietary treatment of a disease or condition for which nutritional requirements are established by medical evaluation, based on recognized scientific principles.

Food composition of the present invention is not limited to compositions containing nutritious substances specifically listed in the present invention. Any nutrients can be delivered as part of the composition to meet the nutritional needs and/or to optimize nutritional status in the subject.

In some embodiments, the food composition mo�et to be delivered preterm infants from birth to at least about three months adjusted age. In another embodiment of the nutritional composition may be delivered to a subject as there is a need to correct nutritional deficiencies. In yet another embodiment of the nutritional composition may be delivered to the infant from birth until at least one year adjusted age.

Food composition of the present invention can be standardized to a specific caloric content, it can be provided as a ready to use product, so it can be provided for the concentrated form. In one embodiment of the present invention provides a method for preparing a food composition containing phase (i) establishing an aqueous dispersion of between about 1 and about 30 mg/l protein substrate containing at least 90 mass % of α-lactalbumin in the volume phase, (ii) bringing the pH of the dispersion to between about 4.2 and about 4.5, (iii) adding between about 75 and about 300 mg/100 ml of the lipid component, and (iv) emulsifying the lipid component for the formation of droplets of the lipid component, size in the range from about 0,070 to about 1 micron in diameter.

In another embodiment of the present invention provides a dietary Supplement for enteral administration containing emulsion of dietary fatty acids in an aqueous component that contains additional�to accept nutrients are designed to fit the nutritional needs of the baby. In one embodiment, the implementation of the food composition of the present invention contains DHA, ARC, arginine and glutamine, in which arginine and glutamine can be provided in the form of oligopeptides.

Food composition and methods of the present invention provide significant advantages compared with the prior art, by addressing and correcting nutritional deficiencies in currently available products.

Additionally, the food composition in accordance with the present invention provides valuable nutrients for premature infants who otherwise would not have received such nutrients, relying on the existing sources of the SPT. The following examples are given to illustrate the invention the present invention but should not be interpreted as limiting it.

Examples

Table 1 provides four options for implementation as an example of the liquid food composition according to the present invention. The concentration of each component listed in the table and have units of g/kg/day. Additionally, each composition described in Table 1, was normalized to lead to equimolecular with arginyl-glutamine. Embodiments of the food composition described� in Table 1 suitable for administration to animals, such as pig or rodent as a model.

Table 1
Embodiments of the food composition
CompositionCitric acidα-LactalbuminDHASCO®Arginyl-glutamineAlanyl-glutamineArginine
10,030,010,250,000,720,58
20,000,010,251,000,000,00
30,040,010,250,001,801,44
40,000,010,252,50 0,000,00

DHASCO® refers to a mixture of oil extracted from unicellular marine algae Crypthecodinium cohnii and sunflower oil with high oleic acid content. The resulting mixed oil contains about 40-45% DHA by weight of the product. DHASCO® commercially available from Martek Biosciences Corporation.

Table 2 provides another arrangement example of the liquid food composition according to the invention. Table 2 provides a variant implementation of the food composition, which is suitable for administration to a human infant. The concentration of each component listed in the table and expressed in units of mass %.

Table 2
Variant implementation of the food composition containing the ARC
Citric acidα-LactalbuminDHASCO®ARASCO®Alanyl-glutamineArginine
0,670,79,34,614,624,3

ARASCO® belongs to the AGR�and oil extracted from a single-celled fungus Mortierella alpina and HOSO, and contains the ARC for 38-33% by weight. ARASCO® does not contain detectable levels of eicosapentaenoic acid (EPA) or other DSPNIC. DHASCO® and ARASCO® was after the healthy babies in the same way as other food triglycerides.

Table 3 provides a variant implementation of the food composition that is optimized for the introduction of a small volume of a human baby. Variant implementation of Table 3 can be entered, for example, at a dose of about 1.5 ml, twice a day, the baby weighs about 1 kg, which consumes about 100 kcal/day. The concentration of each component is given as the interval mass %.

Table 3
Variant implementation of the food composition for human infant weighing 1 kg
α-LactalbuminDHAThe ARCAlanyl-glutamineArginine
0,28-0,700,8-3,81,3-1,912-1820-30

More specifically, the food composition as described in Table 3, can contain about�olo 24.3% of arginine, about 14.6% of glutamine, about 13.8% of the lipid component and about 0,69% α-lactalbumin. In another embodiment of the nutritional composition described in Table 3, can contain about 0,250 g of arginine, approximately 0,150 g of alanyl-glutamine, about 0,0955 g DHASCO, about 0,0469 g ARASCO and about 0.007 g of α-lactalbumin.

In yet another embodiment of the nutritional composition may be adapted for delivery of a human baby weighs around 1 kg, where the baby gets 2 doses of approximately 1 ml of the nutritional composition per day, and where the baby gets about 150 kcal/day. In this embodiment of the nutritional composition may contain about 0,250 g of arginine, approximately 0,150 g of alanyl-glutamine, about 0,0955 g DHASCO, about 0,0469 g ARASCO and about 0.007 g of α-lactalbumin.

All references cited in this description, including without limitation all papers, publications, patents, patent applications, presentations, texts, reports, manuscripts, brochures, books, Internet publications, journal articles, periodicals, etc., thereby incorporated by reference into the present description in full. The discussion links in the present invention is intended only to summarize the assertions made by their authors, and do not make any assumptions that any reference constitutes prior art. Applicants retain the right to dispute the accuracy and relevance of PR�of references cited.

Although preferred embodiments of the invention have been described using specific terms, devices, and methods, such description is provided for illustrative purposes. The words used are words of description and not of limitation. It should be understood that changes and variations can be made by experts in the art, without departing from the essence or scope of the present invention, which are formulated in the following claims. In addition, it should be understood that aspects of various embodiments may be fully or partially interpenetrate. For example, although methods of industrial production of sterile liquid dietary Supplement made in accordance with the methods given in the examples, discusses other applications. Therefore, the nature and scope described in the claims should not be limited to the description of the preferred versions contained in the description.

1. A liquid nutritional composition comprising:
emulsion containing docosahexaenoic acid, where the emulsion is dispersed in an aqueous component containing at least one amino acid component selected from the group consisting of: arginine, arginyl-glutamine and alanyl-glutamine; and
protein a surfactant, the content�containing at least about 90 mass % of α-lactalbumin, thus α-lactalbumin is present in amounts between about 0.1% and about 1.0% of the food composition.

2. A composition according to claim 1, in which the protein surfactant contains at least about 95 mass % of α-lactalbumin.

3. A composition according to claim 1, in which the protein surfactant contains at least about 98 mass % of α-lactalbumin.

4. A composition according to claim 1, further comprising at least one prebiotic.

5. A composition according to claim 1, further comprising vitamins and minerals.

6. A composition according to claim 1, further comprising at least one ω-6 fatty acid.

7. A composition according to claim 1, further comprising arachidonic acid.

8. Method of providing additional power to a subject, comprising administering to the subject a liquid food composition containing:
emulsion containing docosahexaenoic acid, in which the emulsion is dispersed in an aqueous component containing at least one amino acid component selected from the group consisting of: arginine, arginyl-glutamine and alanyl-glutamine; and
protein a surfactant containing at least about 90 mass % of α-lactalbumin, α-lactalbumin is present in amounts between about 0.1% and about 1.0% of the food composition.

9. A method according to claim 8, in which Belk�qau surfactant contains at least about 95 mass % of α-lactalbumin.

10. A method according to claim 8, in which the protein surfactant contains at least about 98 mass % of α-lactalbumin.

11. A method according to claim 8, wherein the composition further comprises at least one prebiotic.

12. A method according to claim 8, wherein the composition further comprises vitamins and minerals.

13. A method according to claim 8, wherein the composition further comprises at least one ω-6 fatty acid.

14. A method according to claim 8, wherein the composition further comprises arachidonic acid.

15. Method of providing additional power prematurely born baby, where the method comprises the enteral administration prematurely born baby liquid food composition containing:
emulsion containing docosahexaenoic acid, in which the emulsion is dispersed in an aqueous component containing arachidonic acid and at least one amino acid component selected from the group consisting of: arginine, arginyl-glutamine and alanyl-glutamine; and
protein a surfactant containing at least about 95 mass % of α-lactalbumin, α-lactalbumin is present in amounts between about 0.1% and about 1.0% of the food composition.

16. A method according to claim 15, in which the protein surfactant contains at least about 98 mass % of α-lactalbumin.

1. A method according to claim 15, where the composition further comprises at least one prebiotic.

18. A method according to claim 15, where the composition further comprises vitamins and minerals.

19. A method according to claim 15, where the composition further comprises alanyl-glutamine dipeptide.

20. A method according to claim 15, where the composition further comprises arginyl-glutamine dipeptide.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a combination of leucine source and ω-3 polyunsaturated fatty acid source applicable in therapeutic or preventive treatment of hypercalcemia.

EFFECT: invention provides extending the range of products applicable in the therapeutic or preventive treatment of hypercalcemia.

19 cl, 8 dwg, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention concerns rehabilitation of elderly patients with ischemic heart disease (IHD) accompanied by chronic heart insufficiency (CHI) following myocardial in myocardial infarction (MI). That is ensured by administering Omacor, a preparation of omega-3-polyunsaturated fatty acids in the remote period, 6 or more months after the suffered MI with underlying a standard drug therapy 60 minutes before the graduated walking.

EFFECT: this complex of the drug preparations combined with the graduated physical exercises provides higher tolerance to physical exercises, improving the cardiovascular function and normalising the lipid exchange that in turn leads to reducing a number of unfavourable cardiovascular episodes and delaying CHI.

2 ex, 5 tbl

FIELD: medicine.

SUBSTANCE: invention represents an agent for treating septic wounds, pus pockets and trophic ulcers containing betaine hydrochloride, methyluracil, trimecaine, pepsin powder and polyethylene oxide 400 with the ingredients taken in certain proportions, wt %, and polyethylene oxide 400 is taken in an amount of 87.0-84.0 ml.

EFFECT: invention provides fastening necrolysis, intensifies bactericidal action, stimulates regeneration, prevents secondary infection.

4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method for bioencapsulation of betaine. Said method is characterised by that betaine is dissolved in dimethylsulphoxide, then dispersed in a mixture of sodium alginate and butanol in the presence of E472c, followed by addition of ethanol and water, and filtering and drying the obtained suspension of microcapsules.

EFFECT: invention provides a simple and fast process of producing betaine microcapsules and increases mass output.

6 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions is based on using as a part of compositions, combinations and devices related to a phenotype involving a decrease of body fat and plasma triglycerides, and an increase of saturation of two or more chemically synthesised or chemically modified polynucleotides, which are specifically hybridised with two or more polynucleotide targets, which are differentially expressed in animals showing the phenotype involving the decrease of body fat and plasma triglycerides and the increase of saturation as a result of the continuous regular administration of a substance which has an effect on one or more parameters of nutrient absorption, saturation, lipid metabolism and fat recovery, wherein the polynucleotide targets contain a gene specified in genes coding FAS proteins, vistafin and GPR119.

EFFECT: group of inventions enables identifying the new compounds having the effect on one or more of these parameters and modulating the related animal's phenotype.

17 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new compounds of formula I, wherein R1 and R2 are identical or different and specified in an alkyl or alkenyl hydrocarbon chain; the R3 group values split by lipase are specified in the patient claim. R4 and R5 are independently hydrogen or C1-C7alkyl; R6 represents hydrogen or C1-C7alkyl; and R7 and R8 are independently hydrogen or C1-C7alkyl. The invention also refers to using compounds of formulas ,

which are introduced into the mammalian biological system and increase the cell concentrations of specific sn-2 substituted ethanolamine-plasmalogens.

EFFECT: compounds are applicable in treating or preventing the age-related disorders associated with high membrane cholesterol, high amyloids and low plasmalogens, such as neurodegeneration, cognitive disorder, dementia, cancer, osteoporosis, bipolar disorder and vascular diseases.

11 cl, 18 dwg, 7 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to gastroenterology, and can be used for the treatment of chronic constipation and functional anorexia. For this purpose, as medicinal nutrition used is a milk-vitamin mixture with the following composition (g per 100 g of the product): Proteins 24-26, Fats 27-29, Carbohydrates 33-34, minerals (mg per 100 g of the product), calcium 940-970, phosphorus 780-820, sodium 230-270, potassium 1370-1550, chloride 1270-1350, magnesium 100-125, iron 9.5-10.7, zinc 2.7-3.5, iodine 145-173, copper 76-87, manganese 45-52, vitamins (mcg per 100 g of the product) D3 7.6-8.2, E 6.2-6.8, C 42-46, B1 960-990, B2 1150-1250, Niacin11-15, B6 1370-1440, Folic acid 125-150, Pantothenic acid 2250-2370, B12 1.5-1.9, Biotin 25-31, Choline 40-45.

EFFECT: invention provides an increase of treatment efficiency.

3 ex

FIELD: medicine.

SUBSTANCE: treating secondary mitochondrial dysfunction in the children suffering an urinogenital pathology is ensured by measuring a pre-therapeutic level of reactive oxygen intermediate (ROI) generation by whole capillary blood leukocytes by luminol-dependent chemoluminescence stimulated by barium sulphate crystals and antioxidant activity (AOA) of serum by chemiluminescence activated by rhodamine B in the presence of ferrous iron ions. If ROI is more than 2.7×105 quantum/sec × 4π, AOA is less than 29 relative units, an energotropic therapy is prescribed in the form of oral administration of 30% carnitine 30 mg/kg/day for one month; thereafter ROI and AOA is re-measured. If ROI is less than 2.7×105 quantum/sec × 4π, AOA is more than 29 relative units, the treatment is terminated; if ROI is more than 2.7×105 quantum/sec × 4π, and AOA is less than 29 relative units, continuing the carnitine therapy is indicated in the same dose for another month.

EFFECT: invention enables optimising the drug-induced treatment of secondary mitochondrial dysfunction in the children with congenital urogenital abnormalities by the individual approach, and grounds prescribing the energotropic therapy and its length.

3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to compositions for local application for the prevention and treatment of local eye pathologies, in particular inflammatory keratites and conjunctivitis and the dry eye syndrome, which contain as active ingredients polyunsaturated fatty acids of the omega-3 and omega-6 type, namely, EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid) and GLA (γ-linolenic acid), mixed with vitamin E acetate and combined into a stable composition in a hydrogel, that is in the disperse form in a water solution, containing one or more gel-forming polymers. The claimed compositions are especially recommended for application as artificial tears.

EFFECT: invention provides an increased efficiency of the prevention and treatment of eye pathologies.

15 cl, 15 tbl, 3 dwg, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to compositions for local application for the prevention and treatment of local eye pathologies, in particular inflammatory keratites and conjunctivitis and the dry eye syndrome, which contain as active ingredients polyunsaturated fatty acids of the omega-3 and omega-6 type, namely, EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid) and GLA (γ-linolenic acid), mixed with vitamin E acetate and combined into a stable composition in a hydrogel, that is in the disperse form in a water solution, containing one or more gel-forming polymers. The claimed compositions are especially recommended for application as artificial tears.

EFFECT: invention provides an increased efficiency of the prevention and treatment of eye pathologies.

15 cl, 15 tbl, 3 dwg, 7 ex

FIELD: nanotechnology.

SUBSTANCE: shell of the nanocapsules is used as apple or citrus high- or low-esterified pectin, and the core - as L-arginine. According to the inventive method, L-arginine is suspended in benzene, the resulting mixture is dispersed into a suspension of apple or citrus high- or low-esterified pectin in benzene in the presence of the preparation E472s while stirring 1000 revolutions per second. Then carbon tetrachloride is added, the resulting suspension of the nanocapsules is filtered and dried at room temperature. The process is carried out for 15 minutes.

EFFECT: simplification and acceleration of the process of producing the nanocapsules, and increase in the yield by weight.

6 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiovascular surgery and cardiology, and deals with complex correction of immunoinflammatory responses of cardiovascular bed. For this purpose, in case of presence of high level of circulating immune complexes and/or complement in patient, three sessions of plasmapheresis in accordance with conventional methods, and in case of low level of IgG and reduced phagocytic activity of neutrophils and monocytes, as well as in case of confirmed autoimmune process, a course of intravenous infusions of human polyvalent immunoglobulin is carried out in accordance with conventional schemes.

EFFECT: method provides reduction of both hypo- and hyperactive disorders in immune system of patients and resulting increase of efficiency of treatment of cardiovascular system diseases.

3 ex

FIELD: medicine.

SUBSTANCE: stimulating the excised liver regeneration is ensured by a 70% hepatectomy into a laboratory animal on the second day of the experiment. A liver regeneration stimulator is presented by L-norvaline administered intragastrically in a daily dose of 10.0 mg/kg every 46 hours for the first 7 days of the experiment.

EFFECT: method provides the effective stimulation of the excised liver regeneration evidenced by reducing the animals' lethality, improved hepatic microcirculation, reduced manifestation of cytolysis and enhanced synthetic function of the liver.

2 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to method of obtaining L-arginine nanocapsules in sodium alginate envelope. In the process of method realisation L-arginine is suspended in benzene. Obtained mixture is dispersed into suspension of sodium alginate in hexane in presence of preparation E472c with mixing at 1000 rev/sec. After that, chloroform is added, and obtained suspension of nanocapsules is filtered and dried at room temperature. Process is realised for 15 minutes.

EFFECT: method in accordance with invention provides simplification and acceleration of process of obtaining nanocapsules and increased output by weight.

3 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to capsule for application with inhalator of dry powder, which contains composition in form of dry powder for pulmonary introduction, which contains mechanosynthesised microparticles, consisting of antibiotic and magnesium stearate.

EFFECT: invention relates to method of obtaining claimed capsule and its application in treatment of bacterial infection, associated with certain lungs diseases.

10 cl, 4 ex, 3 tbl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with stable composition for provision of subject with therapeutically or prophylactically effective amount of alpha-1 protease inhibitor (API), containing alpha-1 protease inhibitor (API) and at least one amino acid, selected from alanine, threonine, serine or hydroxyproline, where said composition includes one or more auxiliary substances, where at least one amino acid is present in composition in the total amount of amino acid from approximately 0.01 M to approximately 3 M. Group of inventions also deals with set for treatment or prevention of API-associated disease or condition, which includes said composition; application of at least one amino acid, selected from alanine, threonine, serine or hydroxyproline, for stabilisation of composition, containing alpha-1 protease inhibitor (API).

EFFECT: group of inventions provides stability of API composition.

15 cl, 27 dwg, 5 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: described is a method of obtaining a composite chitosan-based material, which contains aspartic or glutamine amino acids in a quantity from 2 to 5 wt %, as well as calcium phosphates with a ratio of Ca/P from 1.0 to 1.67. The method consists in barbotage through a suspension of calcium phosphates, obtained in situ in a solution of chitosan and aspartic or glutamic acid, with the following lyophilic drying of the foamed products. Porous matrices can be applied in dentistry, maxillofacial surgery, osteoplastic surgery as implants in the treatment of bone tissue defects.

EFFECT: obtained samples are characterised by a uniform porous structure with the simultaneous reduction of calcium phosphate dimensions to a nano-level with the reduction of the number of material obtaining operations.

2 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: method involves performing a vitrectomy with removing a posterior hyaloids of a vitreous body, and a laser retinal endocoagulation at wave length 532 nm, emitting power 120-200 mWt, pulse length 0.1-0.2 s, spot diameter 150-200 mcm. A chorioretinal venous anastomosis (CRVA) is induced by exposing the branches of the central vein of the retina to the third-order laser light at wave length 532 nm in a number of 4 coagulated, emitting power 500 mWt, pulse length 1 sec and spot diameter 50 mcm. The vitrectomy is preceded by the intramuscular injections of 12.5% etamylate 4ml and the intravenous administration of 0.5% tranexamic acid 1 g 25-30 minutes before. That is followed by the droplet intravenous administration of an infusion solution containing 0.1% perlinganit 10 ml in 0.9% normal saline 100 ml at an initial rate of 5 mcg/min. The area to be exposed to laser is specified at least in 3 diameters of the disk from the optic disk. The third-order laser applications are applied on the branches of the central vein of the retina in a number from 2 to 4 at wave length 532 nm, emitting power 300-400 mWt, exposure 0.5 s, spot diameter 500 mcm in two points in the proximal and distal direction from the CRVA induction point. Immediately before the CRVA induction, a salt-water infusion flow is increased until the central retinal artery starts pulsating. The surgical management is completed by plugging the vitreal cavity with 20% air-gas mixture SF6.

EFFECT: effective management of the clinical course of the retinal venous thrombosis by considerable reduction of postoperative haemophthalmias.

2 ex

FIELD: medicine.

SUBSTANCE: group of inventions relate to field of pharmaceutics, in particular, to pharmaceutical composition for treatment of phenylketonuria, which contains effective quantity of version of Anabaena variabilis (AvPAL) phenylalanine-ammonia-lyase, where claimed version additionally contains polyethylenglycol, as well as pharmaceutically acceptable carrier, which contains stabiliser, where stabiliser represents L-phenylalanine, trans-cinnamic acid or benzoic acid. Also claimed are: method of phenylketonuria treatment and method of reducing phenylalanine concentration in subject's blood.

EFFECT: group of inventions ensure application of prokaryotic PAL, which has higher phenylalanine-converting activity and/or lower immunogenicity in comparison with PAL of wild type.

56 cl, 19 ex, 11 tbl, 19 dwg

FIELD: medicine.

SUBSTANCE: invention is intended for endoscopic haemostasis in case of gastroduodenal bleedings of non-varicose aetiology, peptic ulcer, erosive injuries of upper organs of gastrointestinal tract (GIT). Endoscopic injections of medications in area of ulcer defect are performed. 0.2% solution of noradrenalin in quantity 1 ml per injection is introduced paravasally in 3 points around source of bleeding, as well as in submucous layer on defect edges, with the total volume of introduced solution 7-8 ml.

EFFECT: method makes it possible to obtain more stable endoscopic haemostasis, reduce bleeding recurrences and postoperative complications.

1 ex

FIELD: food industry.

SUBSTANCE: invention relates to nutritional additives for premature babies. The components set envisaged for obtainment of nutrition for premature babies which is adapted to babies' weight in terms of protein content and/or caloric content includes the base nutritional composition and a protein additive containing protein in an amount of at least 50% of the total caloric content of the protein additive and at least 50 wt % of protein in terms of dry substance of the protein additive. Additionally, the set contains instructions on addition of at least a part of the said protein additive to the base nutritional composition. The said instructions involve instructions on the protein additive addition to the base nutritional compositions in such quantity that protein quantity present in the enriched nutritional composition is one of the chosen from the group consisting of: 14% - 16% of the total caloric content for administration to babies weighing less than 1000 g, 12% - less than 14% of the total caloric content for administration to babies weighing 1000 - 1800 g and up to 12% of the total caloric content for administration to babies weighing from more than 1800 to 2500 g. The said instructions involve instructions on the protein additive addition to the nutritional composition in such quantity that quantity of protein to be administered to premature babies is one of the group consisting of: 4.0 - 4.5 g of protein per 1 kg of baby weight a day for administration to babies weighing less than 1000 g, 3.5 - less than 4.0 g of protein per 1 kg of baby weight a day for administration to babies weighing 1000 - 1800 g and 2.0 - 3.4 g of protein per 1 kg of baby weight a day for administration to babies weighing from more than 1800 to 2500 g.

EFFECT: invention allows to optimise alimentation of premature babies taking into consideration babies' weight.

20 cl, 1 tbl, 4 ex

Up!